A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Prescient Therapeutics, Ltd.
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
4SC AG
Kyowa Kirin Co., Ltd.
Genmab
Genmab
Atara Biotherapeutics
Elorac, Inc.
4SC AG
AbbVie
Acrotech Biopharma Inc.
Acrotech Biopharma Inc.
Neumedicines Inc.
Merck Sharp & Dohme LLC
Angimmune LLC
Progen Pharmaceuticals
Morphotek
Valerio Therapeutics
INSYS Therapeutics Inc
Emergent Product Development Seattle LLC
Eisai Inc.
Eisai Inc.